Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 5Phase EARLY_PHASE1 2Phase 3 2Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Completed 7Recruiting 5Active not recruiting 3Withdrawn 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Optic Nerve Glioma 1Oligodendroglioma 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 5pembrolizumab 4Biopsy 4durvalumab 3atezolizumab 3Radiotherapy 3Radiosurgery 3Cyclophosphamide 3Bevacizumab 3palbociclib 2niraparib 2abemaciclib 2Trastuzumab 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Melphalan 2Letrozole 2Ketamine 2Irinotecan 2Hydrocortisone 2Gemcitabine 2Ferrosoferric Oxide 2Dexamethasone 2Curcumin 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Withdrawn × Temozolomide × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

NCT02976441 2017-02-20

Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas

Washington University School of Medicine

Phase EARLY_PHASE1 Withdrawn
CNS

Astrocytoma, Ependymoma, Glioma, Oligodendroglioma, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡